Article Text

Download PDFPDF

741 First in humaun phase I trial of DT-9081, a selective EP4 receptor antagonist in patients with recurrent and or metastatic solids tumors
  1. Jean-Pierre Delord1,
  2. Christophe Le Tourneau2,
  3. Nuria Kotecki3,
  4. Patricia Zerr4,
  5. Claire Jouffroy Zeller4,
  6. Samira El Farouk4,
  7. Asmaa Boudribila4 and
  8. Jean-Pascal Machiels5
  1. 1Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France
  2. 2Department of Drug Development and Inn, Paris, France
  3. 3Institut Jules Bordet, Brussels, Belgium
  4. 4Domain Therapeutics, Strasbourg, France
  5. 5Cliniques Universitaires Saint Luc, Brus, Brussels, Belgium


Background Overexpression of Prostaglandin E2 (PGE2) in tumour tissues suppresses anti-tumour immunity in the tumour microenvironment and can lead to disease progression. DT-9081 is small molecule, orally administered, highly selective antagonist of prostaglandin E receptor 4 (EP4R) developed to overcome the immune-suppressive effects of PGE2, and to reverse the resistance to immune checkpoint blockers.DT-9081 has recently demonstrated significant anti-tumor activity in vivo as monotherapy and in combination with immunotherapeutic agents in several mouse tumor models.

Methods This first-in-human phase 1, multicentre, open label trial is evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of DT-9081 in adult’s patients with recurrent and/or metastatic solid tumours who failed standard of care therapies (EudraCT Number 2022-000092-40) Patients will be dosed orally once daily. The schedule might be adjusted in case of toxicities or based on PK parameters.

This Phase 1 consists of 2 parts. The first part will consist in an initial dose-escalation phase using a 3+3 designup to 6 dose escalation cohorts at increasing levels are planned. The primary objectives will be to determine the dose-limiting toxicities, maximal tolerated dose, and the toxicity profile (NCI CTCAE v5.0) to establish the recommended phase II dose (RP2D) as single agent. Adjustment of the doses will be based on toxicities, pharmacokinetics data and pharmacodynamics effects of DT-9081.

The second part will be an expansion phase at the RP2D in a homogeneous patient population to validate the dose/schedule of administration as well as to assess preliminary efficacy of DT-9081 according to RECIST1.1.

Ethics Approval UNDER REVEW

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.